Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913393 · ClinicalTrials.gov registry record · Phase 2
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
A Phase 2 study, sponsored by Kyntra Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00913393 is a Phase 2 study that was terminated before completion, run by Kyntra Bio. The registered enrollment target is 46 participants.
The verdict
NCT00913393, a Phase 2 study, was terminated before completion, sponsored by Kyntra Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
Interventions
- DRUG Placebo
- DRUG FG-3019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00913393
The ClinicalTrials.gov registry entry for NCT00913393 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00913393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00913393 about?
NCT00913393 is a clinical study titled "Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy". The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
What is the current status of trial NCT00913393?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2009-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00913393?
The interventions under investigation include: Placebo (DRUG), FG-3019 (DRUG).
Who is sponsoring clinical trial NCT00913393?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.